UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Quick Stats
Jun 24, 202656.9
AI Score
HOLD0.81
Volume Ratio
Aug 06, 2026
Next Earnings
16
+ve Days (30d)
14
-ve Days (30d)
URGN Stock Summary
Last updated Jun 24, 2026
URGN is currently trading at $35.42, positioned above its 200-day moving average of $22.35, indicating a long-term uptrend. The stock has a 52-week range of $12.73 to $36.08.
Technical Analysis: The 50-day moving average stands at $27.65, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 77.247, suggesting the stock is in overbought territory (bullish but caution advised).
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.05, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates URGN at 56.9/100 with a HOLD recommendation.
URGN (UroGen Pharma Ltd. Ordinary Shares) Indicators
Last updated Jun 24, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 77.247 |
| CMF (20) | 0.05 |
| ROC (10) | 25.692 |
| ADX (14) | 42.73 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 2.11 |
| AROONOSC (14) | 100.0 |
| WILLAMS %R (14) | -6.811 |
| MFI (14) | 92.996 |
URGN Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
URGN Price vs Max Options Open Interest
URGN Max Change In Options Open Interest
URGN Options - Sort by Max open Interest (near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
URGN Daily Out of Money Options - Sort by Max open Interest (near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
URGN Daily In the Money Options - Sort by Max open Interest (near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
URGN Most Active Options by Volume(near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
UroGen Pharma Ltd. Ordinary Shares is above both 50 Day and 200 Day SMA which is considered Bullish.
URGN Moving Averages Analysis
UroGen Pharma Ltd. Ordinary Shares has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jun 24, 2026
UroGen Pharma Ltd. Ordinary Shares has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jun 24, 2026
URGN (UroGen Pharma Ltd. Ordinary Shares) Simple Moving Averages
Moving Averages are last updated Jun 24, 2026
| Days | MA |
|---|---|
| 10 | 32.2 |
| 20 | 29.91 |
| 30 | 29.76 |
| 50 | 27.65 |
| 100 | 23.65 |
| 200 | 22.35 |
URGN Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 1.7 billion |
| Earnings/Share ($) | -2.74 |
| Net Proft Margin (%) | -0.9483 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.905 |
| EPS Estimate Next Year ($) | 1.2288 |
| WallStreet Target Price ($) | 36.875 |
| Most Recent Quarter |